Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Biosplice Announces Collaboration with Novo Nordisk in Diabetes
06:00am, Thursday, 13'th Jun 2024
SAN DIEGO, June 13, 2024 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhib
ASML, Novo Nordisk, Spotify Boast This Sign Of Stock Market Leadership
01:50pm, Wednesday, 12'th Jun 2024
Spotify stock, ASML and Novo Nordisk, are in or near buy zones and boast this key signal of stock market leadership.
US Senate panel to weigh Novo Nordisk subpoena over Ozempic, Wegovy prices
10:57am, Tuesday, 11'th Jun 2024
The U.S. Senate health panel said on Tuesday it would vote later this month on whether to subpoena Novo Nordisk over the high U.S. prices for weight loss drugs Ozempic and Wegovy compared to those off
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
10:05am, Monday, 10'th Jun 2024
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Novo Nordisk A/S - share repurchase programme
08:15am, Monday, 10'th Jun 2024
Bagsværd, Denmark, 10 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of
The Safety Net Seven: 7 Stocks to Own for Unshakeable Returns
06:00am, Monday, 10'th Jun 2024
With so many moving parts in the market, investors shouldn't just focus on explosive growth ideas. Instead, they should turn to the safety of, well, safe stocks to buy.
Novo Nordisk Boss on Ozempic and Eating Disorder Criticism, Social Media Pressure
08:06am, Sunday, 09'th Jun 2024
#Ozempic #Wegovy #obesity #diabetes #weightloss #healthcare #pharmaceuticals #novonordisk #drugs #leadership #CEO Novo Nordisk has revolutionized the weight loss market with its blockbuster diabetes a
Here's Why Demand for Ozempic and Wegovy Could Soar Even Higher
09:00am, Saturday, 08'th Jun 2024
Novo Nordisk has two hugely successful assets in Ozempic and Wegovy. A recent trial also found semaglutide effective for treating chronic kidney disease.
ECB Rate Cut Propels European Markets: 3 Must-Watch Stocks
09:16am, Friday, 07'th Jun 2024
Historic ECB rate cut bolstered European stocks, which calls for keeping a tab on Siemens (SIEGY), ASML Holding (ASML) and Novo Nordisk (NVO) for solid growth.
Ozempic, Wegovy Really Good Value: Novo Nordisk CEO
08:04am, Friday, 07'th Jun 2024
#Ozempic #Wegovy #obesity #diabetes #weightloss #healthcare #pharmaceuticals #novonordisk #drugs #leadership #CEO Novo Nordisk is Europe's most valuable company with booming demand for its blockbuster
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
05:23pm, Thursday, 06'th Jun 2024
Pharma stocks have two unique characteristics that can make them great investments for many individuals. First, unlike the vast majority of equities, undervalued pharma stocks can rally even when the
Novo Nordisk's Ozempic sales double to $700 M in China, driven by weight-loss demand
09:33am, Thursday, 06'th Jun 2024
Last year, Novo Nordisk, the Danish pharmaceutical giant, witnessed a significant surge in the sales of its diabetes drug Ozempic in China, doubling its revenue to almost $700 million. This remarkable
Ozempic Just Got Even More Bullish For Novo Nordisk Stock, Yet Again
07:00am, Thursday, 06'th Jun 2024
Novo Nordisk is working hard to expand Ozempic's addressable market. The drug is helpful in treating chronic kidney disease, per a new trial.
Ozempic, Wegovy Weight-Loss Revolution: Novo Nordisk CEO Interview
06:21am, Thursday, 06'th Jun 2024
#Ozempic #Wegovy #obesity #diabetes #weightloss #healthcare #pharmaceuticals #novonordisk #drugs #leadership #CEO Novo Nordisk is Europe's most valuable company with booming demand for its blockbuster
European stocks open higher as markets anticipate first ECB rate cut since 2019; Novo Nordisk up 3.5%
03:24am, Thursday, 06'th Jun 2024
European stocks opened higher Thursday, with markets anticipating the ECB will cut borrowing costs for the first time since September 2019.
